CAM-PaC uses the following methods:

  • Cell-based model systems utilising pancreatic tumour (stem) cell lines with altered expression of target genes will be used to identify molecular functions, assess affected signalling pathways, and monitor effects on tumourigenicity and clonogenic growth mediated by the target genes.
  • Genetically engineered mouse models (GEMM) with novel modes for temporal and spatial control of transgene activation will be produced to validate the roles of target genes in tumour initiation, progression and differentiation in vivo.
  • Patient-derived xenografts will be used in pre-clinical therapeutic trials to address the exceptionally high inter- and intratumour heterogeneity in human PDAC and to identify novel determinants of therapy resistance in individual tumours.
  • Large scale metabolomic in addition to transcriptomic and genomic profiling of resulting cellular and animal phenotypes will be performed in order to close the large gaps of knowledge that exist in this area.
  • Large scale data integration and modelling of clinical, histopathological, biological and genome-wide molecular data of primary and xenograft tumours to identify novel therapeutic targets and predictive models.